E
EKR Therapeutics
ekrtx.com - Deze website is te koop! - de beste bron van informatie over ekrtx.
About EKR Therapeutics
EKR Therapeutics, Inc. was a specialty pharmaceutical company concentrating on the acute-care hospital market. Founded in late 2005 by Howard Weisman, S. Douglas Sheldon, and Dr. Jeffery Z. Li, the company focused on acquiring, developing, and commercializing products for critical care. Howard Weisman, who served as Chairman and CEO, brought significant industry experience to the firm, having previously co-founded ESP Pharma and held various roles at Merck and Pfizer. This background in cardio-neurovascular products and specialty pharmaceuticals shaped EKR's strategy of addressing unmet needs in hospital settings.
The company's business model revolved around acquiring and marketing proprietary products directly to hospitals, with a focus on areas like cardiovascular health, pain management, and oncology supportive care. EKR's revenue was generated through the sales of its product portfolio, which it built through a series of acquisitions. This strategy was designed to create a commercially focused organization that could enhance the therapeutic value of acute-care treatments.
EKR's product lineup included Cardene I.V. (nicardipine hydrochloride), an intravenous treatment for short-term hypertension, and Retavase, a drug for managing acute myocardial infarction (AMI). In 2008, the company received FDA approval for a ready-to-use premixed intravenous bag for Cardene I.V., simplifying its administration in critical care settings. The portfolio also featured DepoDur, an extended-release morphine for post-operative pain, and Gelclair, a bioadherent oral gel to manage pain from oral mucositis, often a side effect of cancer treatments. In 2011, sales were primarily driven by Cardene I.V., generating $58 million in net revenue.
A significant milestone in the company's history was its acquisition by Cornerstone Therapeutics Inc. in June 2012. The deal was valued at up to $150 million, consisting of a $125 million initial cash payment and up to $25 million in potential milestone payments tied to Retavase sales. This acquisition expanded Cornerstone's footprint in the hospital therapeutics market, integrating EKR's cardiovascular products and sales infrastructure into its operations, at which point EKR became a wholly owned subsidiary. The company had previously secured substantial funding from venture capital and private equity firms, including a $50 million Series D round in 2008, to finance its product acquisition strategy.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | May 2012 | $150M | $150M | Cornerstone Therapeutics | — |
| DEBTDebt | Mar 2008 | $95M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for EKR Therapeutics is 250 monthly website visits. EKR Therapeutics's team declined 23.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
EKR Therapeutics in the Bedminster Township ecosystem
The EKR Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- NVNewSpring Ventures
- EPESP Equity Partners
Series B and later3 investors entered at this stage
Quaker Bio Ventures
Merrill Lynch
NewSpring Capital
Other known investors1 additional known investor
Cornerstone Therapeutics
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about EKR Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EKR Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






